Transcriptome profiling by RNA sequencing reveals novel targets of Gemini nano curcumin on p53-mutant HT-29

Hewa Jalal Azeez1, Raheleh Karimzadeh2, Esmaeil Babaei3

  • 1Department of Biology, School of Natural Sciences, University of Tabriz, Tabriz, Iran; Erbil Teaching Hospital, Ministry of Health, Erbil, Iraq.

Abstract

Insights

Gemini Nano-Curcumin (Gemini-Cur) impacts colorectal cancer cells by altering endoplasmic reticulum response and transporter-related genes. This study identifies potential new therapeutic targets for treating aggressive colorectal cancer.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Pharmacology

Background:

  • Colorectal cancer (CRC) is a leading cause of cancer mortality worldwide.
  • Gemini Nano-Curcumin (Gemini-Cur) has demonstrated effects on CRC cell viability.
  • The precise molecular mechanisms of Gemini-Cur toxicity in CRC remain unclear.

Purpose of the Study:

  • To investigate the molecular targets of Gemini-Cur in p53-mutant HT-29 colorectal cancer cells.
  • To utilize RNA sequencing to identify differentially expressed genes (DEGs) and affected pathways.

Main Methods:

  • HT-29 cells were treated with Gemini-Cur.
  • RNA was extracted, and cDNA libraries were sequenced.
  • Differential gene expression analysis was performed using DESeq2.
  • Gene Ontology (GO) and Reactome pathway analyses were conducted.
  • Protein-protein interaction (PPI) networks were constructed and analyzed.

Main Results:

  • 1309 DEGs were identified between treated and untreated cells (479 upregulated, 63 downregulated).
  • GO analysis revealed enrichment in endoplasmic reticulum (ER)-related processes.
  • Pathway analysis indicated modulation of ER stress response and transporter-related genes by Gemini-Cur.
  • Three significant modules were identified in the PPI network.

Conclusions:

  • Gemini-Cur exerts its effects on HT-29 colorectal cancer cells by modulating ER stress response and transporter-related pathways.
  • These findings suggest potential novel therapeutic targets for colorectal cancer treatment.
  • Further research is needed to elucidate the specific molecular mechanisms and proteins involved.